|
|
|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
|
|
|
The Journey of an Aspirational Leader
|
Lynn Seely, MD
President and CEO of Myovant Sciences, Lynn Seely joins Alicia Morgans sharing highlights of her career journey presented in her keynote during the 4th Annual PCF Women in Science Forum at the 26th Annual Prostate Cancer Foundation Scientific Retreat. Dr. Seely shares elements from her career journey including her internship and residency in internal medicine at Yale, her training as a basic scientist, and her joining the faculty at the University of California, San Diego.
|
|
|
|
|
|
|
|
|
|
|
|
The IRONMAN - An International Registry for Men with Advanced Prostate Cancer
|
Dana Rathkopf, MD
Dana Rathkopf and Alicia Morgans discuss the IRONMAN registry. Dr. Rathkopf, a strong contributor to the IRONMAN registry trial, explains the goals of the registry and why it is so important for the personalization of patient care around the world.
|
|
|
|
|
|
|
|
|
|
|
|
The Biology of Prostate Cancer
|
Kenneth Pienta, MD
Kenneth Pienta joins Charles Ryan to discuss the biology of prostate cancer, and to share a clinician's perspective of thinking about the biology of this disease. This is a look at the current year and some of the significant findings that have changed the way we look at treating prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith
|
Matthew R. Smith, MD, Ph.D.
In this conversation with Alicia Morgans, Matthew Smith shares highlights from his 2019 European Society for Medical Oncology annual meeting, presentation; the updated survival results from SPARTAN, A study of apalutamide in men with non-metastatic castration-resistant prostate cancer, a pivotal study which led to the approval of apalutamide for men with nmCRPC.
|
|
|
|
|
|
|
|
|
|
|
| Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
|
| Neeraj Agarwal, MD
|
| Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE |
|
|
|
| Invited Discussant (LBA51, LBA52, 848PD, 849PD and 855PD) – Immunotherapy in mCRPC, PSMA Radionuclide Therapy and an Update M0 STAMPEDE Data
|
| Cora Sternberg, MD
|
| Cora Sternberg summarizes the findings from several posters, including three immunotherapy phase 1 or 2 trials, a phase 2 trial of 177Lu-PSMA-617, and updated longer term data from the M0 standard of care + docetaxel STAMPEDE arm.
|
|
|
|
|
|
| Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
|
| Matthew Smith, MD, Ph.D.
|
| Matthew Smith presents the final MFS analysis and the second interim analysis for overall survival. Not surprisingly, the MFS benefit was sustained. However, this second interim analysis for overall survival with 285 (67%) overall survival events, with a median 41.0 months followup, also did not yet reach the O’Brien-Fleming boundary.
|
|
|
|
|
|
|
|
|
|
|
| Patient-Reported Outcomes From TITAN in Patients with Metastatic Castration-Sensitive Prostate Cancer
|
| Neeraj Agarwal, MD
|
| In the TITAN study, compared with placebo, the addition of apalutamide to ADT significantly improved radiographic progression-free survival (rPFS; HR 0.48, 95% CI 0.39-0.60; p < 0.0001), and overall survival (OS; HR 0.67, 95% CI 0.51-0.89; p = 0.0053) in patients with mCSPC. Neeraj Agarwal and colleagues evaluated pain, fatigue, and overall health-related quality of life of patients in TITAN.
|
|
|
|
|
|
|
|
|
|
|
|
